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The pathogenesis of pulmonary hypertension (PH) includes
an inflammatory response. Thymulin, a zinc-dependent thy-
mic hormone, has important immunobiological effects by in-
hibiting various proinflammatory cytokines and chemokines.
We investigated morphological and hemodynamic effects of
thymulin administration in a rat model of monocrotaline
(MCT)-induced PH, as well as the pattern of proinflammatory
cytokine gene expression and the intracellular pathways in-
volved. Adult Wistar rats received an injection of MCT (60
mg/kg, sc) or an equal volume of saline. One day after, the
animals randomly received during 3wk an injection of saline,
vehicle (zinc plus carboxymethyl cellulose), or thymulin (100
ng/kg, sc, daily). At d 23–25, the animals were anesthetized for
hemodynamic recordings, whereas heart and lungs were col-
lected for morphometric and molecular analysis. Thymulin
prevented morphological, hemodynamic, and inflammatory
cardiopulmonary profile characteristic of MCT-induced PH,
whereas part of these effects were also observed in MCT-
treated animals injected with the thymulin’s vehicle contain-
ing zinc. The pulmonary thymulin effect was likely mediated
through suppression of p38 pathway. (Endocrinology 149:
4367–4373, 2008)
INFLAMMATION SEEMS to play a significant role in thegenesis or progression of some forms of pulmonary ar-
terial hypertension (PAH), namely those associated with
connective tissue diseases and HIV infection (1, 2). There are
several reports that demonstrated the presence of inflam-
matory cells, including macrophages, polymorphonuclear
neutrophils, lymphocytes, and mast cells, in the vicinity of
pulmonary vessels and plexiform lesions (3, 4). Elevated lev-
els of the proinflammatory cytokines IL-1 and -6 (5), fracta-
lkine (6), regulated upon activation normal T cell expressed
and secreted (7), macrophage inflammatory protein-1a (8),
among others, have also been observed in patientswith PAH.
The role of inflammation in pulmonary hypertension (PH) is
further supported by the experimental (9) and clinical (10)
improvements observed after steroid treatment or immuno-
suppressor administration, such as rapamycin (11, 12) or
mycophenolate mofetil (13).
Monocrotaline (MCT) and hypoxia models of experimen-
tal PH share the involvement of inflammation on its patho-
physiology (14, 15). MCT causes endothelial cell damage and
mononuclear infiltration into the perivascular regions of ar-
terioles and muscular arteries. By its turn, IL-1 and IL-6,
strong proinflammatory cytokines, are excessively produced
in animals treated with MCT, and the administration of an
IL-1 receptor antagonist reduced PH and right ventricle hy-
pertrophy (9, 16). Further evidence implicating the inflam-
matory response in the genesis of PH is given by an animal
model in which PH was induced by IL-6 administration
(17, 18). Multiple studies using serum from patients with
PAH have demonstrated increased circulating IL-6 level (5).
Moreover, the genome of human herpes virus type 8, which
encodes a particularly potent viral IL-6 analog, is associated
with PAH in the setting of several diseases, namely HIV/
AIDS (19).
Thymulin, also known as “serum thymic factor” (20–23),
is a nonapeptide, coupled to ion zinc (24), exclusively se-
creted by thymic epithelial cells (25, 26). Thymulin enhances
an antiinflammatory cytoprotective response and depresses
inflammatory cascades (27). Regarding its role in lung dis-
eases, thymulin reduced the cellular inflammatory response
and fibrotic changes in an experimental model of lung fi-
brosis (28). These pulmonary effects were related to an in-
hibition of the local synthesis of various proinflammatory
cytokines and chemokines. Thymulin’s beneficial effects in
other inflammatory disease models were attributed to
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modulation of MAPK family members (29, 30). Thymulin
action is strictly dependent on the presence of the metal zinc
because it induces the conformational changes within the
molecule that are necessary for the full expression of its
biological activity (24). Besides being an integral part of this
thymic hormone, zinc is essential formany enzymes (31), and
plays a role as an antiinflammatory and antioxidant agent
(32). The potential role of thymulin in PH has not been
studied before. Knowing that MCT induces an early and
potent inflammatory response that culminates in severe PH,
and that thymulin is an immunoregulatory peptide, the ra-
tionale of the present study was to evaluate cardiac and
pulmonary effects of thymulin in this experimental model,
and exploit the intracellular signaling pathways involved.
Materials and Methods
Study design
Animal experiments were performed according to the Portuguese
law for animal welfare and conform to the Guide for the Care and Use of
Laboratory Animals published by the U.S. National Institutes of Health
(National Institutes ofHealth PublicationNo. 85-23, revised 1996). Adult
male Wistar rats (Charles River, Barcelona, Spain) weighing 180–200
g were housed in groups of five per cage in a controlled environment
under a 12-h light, 12-h dark cycle at a room temperature of 22 C, with
a free supply of food and water. Rats randomly received a sc injection
of MCT (60 mg/kg body weight; Sigma, Barcelona, Spain) or an equal
volume of vehicle [control (Ctrl) groups]. One day after, animals from
both groups were randomly assigned to receive saline, vehicle, or
thymulin, which was injected sc once a day during 3 wk. Vehicle con-
sisted in a solution of carboxymethyl cellulose and zinc without thymu-
lin. Thymulin (100 ng/kg; Sigma) was prepared using carboxymethyl
cellulose (0.5%) as a carrier and zinc (ZnCl2; 3.8 g/ml) as a cofactor (33,
34).
The protocol resulted in six groups: Ctrl rats injected with saline (Ctrl
plus S) (n  6), Ctrl rats injected with vehicle (Ctrl plus V) (n  6), Ctrl
rats injected with thymulin (Ctrl plus T) (n 6), MCT rats injected with
saline (MCT plus S) (n  8), MCT rats injected with vehicle (MCT plus
V) (n  8), and MCT rats injected with thymulin (MCT plus T) (n  8).
During d 23–25 after MCT or saline injection, the animals were anes-
thetized and submitted to hemodynamic instrumentation.
Hemodynamic studies
Animals were anesthetized with pentobarbital (60 mg/kg, ip; CEVA),
placed over a heating pad, and tracheostomized for mechanical ventilation
with room air (Harvard Small Animal Ventilator, Model 683; Harvard
Apparatus, Holliston, MA). Anesthesia was maintained with additional
bolus of pentobarbital (2 mg/100 g) as needed. Under binocular surgical
microscopy (Wild M651.MS-D; Leica, Herbrugg, Switzerland), the right
jugular vein was cannulated for fluid administration (prewarmed 0.9%
NaCl solution) to compensate for perioperative fluid losses. The heart was
exposed through a median sternotomy and the pericardium widely
opened.Right and left ventricular (RVandLV, respectively) pressureswere
measuredwith a 2F high-fidelitymicromanometer (SPR-324;Millar Instru-
ments, Houston, TX) inserted into RV and LV cavities, respectively. After
complete instrumentation the animal was allowed to stabilize for 15 min.
Hemodynamic recordings were made with ventilation suspended at end
expiration. Parameters were converted on line to digital data with a sam-
pling frequency of 1000 Hz. RV and LV pressures were measured at end
diastole and peak systole. Peak rates of RV and LV pressure increase
(dP/dtmax) and pressure decrease (dP/dtmin) were measured as well. Re-
laxation rate was estimated with the time constant  () by fitting isovolu-
metric pressure decrease to a monoexponential function.
After hemodynamic evaluation was completed, cardiac arrest was
induced by injection of KCl 7.5%. Heart and lungs were excised and
weighed. Under binocular magnification (3.5), the RV free wall was
dissected from the left ventricle and septum, and weighed separately.
Heart, lung, RV, and left ventricle plus septum (LVS) weights were
normalized to body weight, whereas RV weight was normalized to LVS
weight. Samples from lung and right ventricle were collected for mor-
phology and molecular analysis.
mRNA quantification
After collection, samples were quickly immersed in RNAlater (QIAGEN,
Inc., Valencia, CA) and frozen (80 C). Total mRNAwas extracted through
the guanidium-thiocyanate selective silica-gel membrane-binding method
(QIAGEN 74124) according to the manufacturer’s instructions. Concen-
tration and purity were assayed by spectrophotometry (Eppendorf
6131000.012; Eppendorf International, Hamburg, Germany). Two-step
real-time RT-PCRwas used to perform relative quantification ofmRNA.
For each studied mRNA molecule and for each tissue, standard curves
were generated from the correlation between the amount of starting total
mRNA and PCR threshold cycle (second derivative maximum method)
of graded dilutions from a randomly selected tissue sample (r  0.97).
For relative quantification of specific mRNA levels, 50 ng total mRNA
from each sample underwent two-step real-time RT-PCR. A melt curve
analysis of each real-time PCR and 2% agarose gels (0.5 g/ml ethidium
bromide)were performed to exclude primer-dimer formation and assess
the purity of the amplification product. Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH)mRNA levels were similar in all experimental
groups, which enabled the use of this gene as an internal Ctrl. Results
of mRNA quantification are expressed in an arbitrary unit (AU) set as
the average value of the Ctrl group (1 AU) after normalization for
GAPDH. Reverse transcription (20l; 10 min at 22 C, 50min at 50 C, and
10 min at 95 C) was performed in a standard thermocycler (Whatman
Biometra 050–901; Goettingen, Germany): 40 U/reaction of reverse tran-
scriptase (Invitrogen 18064-014; Invitrogen Corp., Carlsbad, CA); 20
U/reaction of ribonuclease inhibitor (Promega N2515; Promega Corp.,
Madison,WI); 30 ng/ml randomprimers (Invitrogen 48190-011), 0.5mm
nucleotide mix (MBI Fermentas R0192; MBI Fermentas GmbH, St. Leon-
Rot, Germany); 1.9 mm MgCl2; and 10 mm dithiothreitol. Of the cDNA
yield, 10% was used as a template for real-time PCR (LightCycler II;
Roche Diagnostics Corp., Roche Applied Science, Indianapolis, IN) us-
ing SYBR green (QIAGEN 204143) according to the manufacturer’s
instructions. Specific PCR primer pairs for the studied genes were:
GAPDH, forward 5-TGG CCT TCCGTG TTC CTA CCC-3 and reverse
5-CCG CCT GCT TCA CCA CCT TCT-3; IL-6, forward 5-CCG TTT
CTA CCT GGA GTT TG-3 and reverse 5-GAA GTT GGG GTA GGA
AGG AC-3; IL-1, forward 5-ATG GCA ACT GTC CCT GAA CTC-3
and reverse 5-AAT CCT TAA TCT TTT GGG GTC TG-3; and fracta-
lkine, forward 5-TGT GTA CTC TGC TGG CGG GTC-3 and reverse
5-GTC TCC AGG ATG ATG GCG CGC T-3.
Immunohistochemistry (IHC) studies
IL-6 immunostainings were performed on formalin-fixed and paraf-
fin-embedded lung. Sections (5 m) were placed on SuperFrostPlus
slides (Menzel Glaser GmbH, Braunschweig, Germany). The primary
antibody, a polyclonal goat anti IL-6 (Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA), was used in a 1:50 dilution. After dewaxing in xylene
and rehydration in ethanol, antigen retrieval was achieved by boiling in
10 mm citrate buffer followed by cool down at room temperature. In-
cubation with the goat ImmunoCruz Staining System (Santa Cruz Bio-
technology) was performed according to the manufacturer’s instruc-
tions. Incubation of the primary antibody occurred at 4 C overnight.
Negative Ctrl reactions included omission of the primary antibody. To
visualize the peroxidase activities in sections, diaminobenzidine tetra-
hydrochloride was used. Sections were counterstained with hematox-
ylin. The slides were observed and photographed with the Olympus
BX61 microscope (Olympus, Hamburg, Germany).
Western blot analysis
Lung tissue samples were processed for Western blot analysis. Pro-
teins were obtained according to Kling et al. (35). Ten micrograms of
protein were loaded onto 10% acrylamide minigels, electrophoresed at
100V at room temperature, and then transferred to Hybond-C Extra (GE
Healthcare Life Sciences, Uppsala, Sweden). Blots were probed with
polyclonal p38, c-JunN-terminal kinase (JNK1/2) andp44/42 (ERK1/2),
and phospho-p38 (dp-p38), phospho-JNK (dp-JNK1/2), and phospho-
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p44/42 (dp-ERK1/2), antibodies (Cell Signaling Technology, Inc., Dan-
vers,MA) according to themanufacturer’s instructions. For loadingCtrl,
blots were probed with -tubulin rabbit polyclonal antibody (1:100,000)
(Abcam plc, Cambridge, UK). Afterwards, blots were incubated with a
secondary horseradish peroxidase conjugate (1:2000) (Cell Signaling
Technology). Membranes probed simultaneously with p38 and JNK, as
well as dp-p38 and dp-JNK, were stripped [62.5 mm Tris-HCl (pH 6.7),
2% sodium dodecyl sulfate, and 100 mm 2-mercaptoethanol] for 30 min
at 50 C and then incubated with -tubulin. Membranes were developed
with Super Signal West Femto Substrate (Pierce, Rockford, IL) and
ChemiDoc XRS System (Bio-Rad Laboratories, Inc., Hercules, CA).
Quantitative analysis was performed with Quantity One 4.6.5 1-D Anal-
ysis Software (Bio-Rad Laboratories).
Statistical analysis
The results were presented as mean sem and were compared using
two-way ANOVA. When treatments were significantly different, the
Holm-Sidak test was selected to perform pairwise multiple compari-
sons. Statistical significance was set at P  0.05.
Results
Morphometric data
Cardiac and lung morphometric data are summarized in
Table 1. Administration of vehicle or thymulin to Ctrl animals
did not affect any of the studied morphometric parameters.
MCT induced a statistically significant increase in heart
and lung weights, when compared with the Ctrl plus S
group. PH induced by MCT resulted in RV hypertrophy
without affecting LV weight. Administration of both vehicle
and thymulin significantly decreasedmorphometric changes
induced by MCT, although the beneficial effects were more
pronounced in thymulin-treated animals.
Biventricular hemodynamics
Hemodynamic data are summarized in Table 2. In Ctrl
groups, neither vehicle nor thymulin modified the studied
hemodynamic parameters. MCT induced a significant in-
crease in peak systolic RV pressure (RVPmax), a parameter
used to estimate PH, as well as in RV dP/dtmax, an index of
RV contractility. Regarding RV diastolic function, relaxation
rate as estimated by the  was prolonged in MCT-treated
animals. MCT-treated animals that received vehicle pre-
sented less PH when compared with the MCT plus S group,
whereas MCT-treated animals that received thymulin did
not demonstrate any hemodynamic evidence of PH. Indeed,
there was no increase in RVPmax or changes in dP/dtmax.
Concerning RV diastolic function,  was not different from
Ctrl animals.
With regard to LV function, the MCT plus S group pre-
sented, when compared with the Ctrl plus S group, lower
systolic and end-diastolic pressures, and smaller peak rates
TABLE 1. Morphometric parameters
Ctrl groups MCT groups
P value
Saline Vehicle Thymulin Saline Vehicle Thymulin
Body wt (g) 287  9 293  4 288  7 269  6 278  9 279  10
Heart wt/body wt (g/kg) 3.01  0.11 2.70  0.06 2.95  0.06 3.83  0.17a 2.89  0.09b 2.99  0.11b c
RV wt/body wt (g/kg) 0.55  0.02 0.62  0.03 0.63  0.03 1.15  0.06a 0.83  0.08b,d 0.67  0.06b c
RV/LVS 0.25  0.03 0.33  0.01 0.30  0.03 0.501  0.02a 0.44  0.05d 0.34  0.02b,e
Lung wt/body wt (g/kg) 4.66  0.16 4.42  0.15 4.45  0.16 12.44  1.01a 7.95  1.05b,d 6.63  0.39b c
Data are presented as mean  SEM. RV, Right ventricle; wt, weight.
a P  0.05 vs. Ctrl plus S.
b P  0.05 vs. MCT plus S.
c Interaction.
d P  0.05 vs. Ctrl plus V.
e P  0.05 vs. MCT plus V.
TABLE 2. Biventricular hemodynamic parameters
Ctrl groups MCT groups
P value
Saline Vehicle Thymulin Saline Vehicle Thymulin
Right ventricle
RVPmax (mm Hg) 25.5  2.1 25.7  0.7 24.9  1.1 46.6  1.9
a 41.9  3.1b,c 26.8  3.6
c,d e
RV-EDP (mm Hg) 1.9  0.5 1.9  0.6 1.6  0.6 1.4  0.4 1.1  0.2 0.8  0.3
dP/dtmax (mm Hg/sec) 1192  80 1012  116 1148  51 1679  149
a 1249  123c 1220  82c
dP/dtmin (mm Hg/sec) 973  85 912  69 900  97 1218  90 1201  141 960  111
 (msec) 12  1 12  2 14  1 27  1a 28  2b 13  1c,d e
Left ventricle
LVPmax (mm Hg) 104.9  6.8 104.3  13.2 107.6  5.2 68.1  8.5
a 76.7  9.8b 94.7  7.3c
LV-EDP (mm Hg) 3.7  0.3 3.5  0.4 3.6  0.6 1.7  0.4a 3.1  0.4 2.6  0.3
dP/dtmax (mm Hg/sec) 5711  589 5654  987 6162  418 3519  338
a 4274  296 5510  460
dP/dtmin (mm Hg/sec) 3349  404 3170  624 3372  249 1950  233
a 2000  318b 3460  399c,d
 (msec) 21  1 18  1 20  1 22  1 22  1 19  1
Data are presented as mean  SEM. LVPmax, LV peak systolic pressure; RV-EDP and LV-EDP, RV and LV end-diastolic pressures,
respectively.
a P  0.05 vs. Ctrl plus S.
b P  0.05 vs. Ctrl plus V.
c P  0.05 vs. MCT plus S.
d P  0.05 vs. MCT plus V.
e Interaction.
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of pressure increase and decrease. The MCT plus V group
kept a significant decrease in peak systolic LV pressure. In
MCT-treated animals that received thymulin, no hemody-
namic disturbances were observed in the left ventricle. There
were no statistically significant differences between this
group and Ctrl plus T animals. The  did not differ among
the groups.
Pro-inflammatory cytokines
Pro-inflammatory cytokines IL-1, IL-6, and fractalkine
mRNA levels were measured in lung and RV myocardial
samples by real-time PCR (Fig. 1).
In lung, MCT treatment induced a significant increase in
IL-6 mRNA, without changing the other analyzed cytokines
(Fig. 1, left panel). In MCT-treated animals, both vehicle and
thymulin induced a statistically significant decrease in IL-6
mRNA expression.
IHCstudieswereperformed to identify thepatternof cellular
expression of IL-6 in the lung. In Ctrl animals (Fig. 2, A–C),
IL-6 is mainly expressed in smooth muscle cells both in
arterial and bronchial walls, and weakly in bronchial epi-
thelial cells and vascular endothelium. In MCT-treated an-
imals (Fig. 2, D–F), a similar patternwas observed. However,
the intensity of this staining seems to be increased in theMCT
plus S group. In contrast to the Ctrl group, the MCT groups
presented an infiltration of mononuclear inflammatory cells
expressing IL-6 protein.
In the right ventricle, MCT administration induced a
strong up-regulated IL-6 expression, and a slight increase in
IL-1 and fractalkine mRNA levels (Fig. 1, right panel). In
MCT-treated animals, both vehicle and thymulin normalized
IL-6 mRNA expression.
MAPK signaling pathway
Pulmonary protein levels of p38, JNK1/2, and ERK1/2
(both unphosphorylated and phosphorylated forms) were
analyzed by Western blot and quantified by densitometric
analysis (Fig. 3).
In Ctrl animals both vehicle and thymulin groups exhib-
ited an increase of phosphorylated p38 protein levels. In
comparison with Ctrl animals treated with saline, MCT an-
imals injected with saline revealed an enhancement of p38
and JNK1/2 phosphorylation, whereas no significant effect
was observed inERKpathway. InMCT-treated animals, both
vehicle and thymulin reduced JNK phosphorylation.
Thymulin induced a specific and strong inhibition of p38
pathway, whereas vehicle did not modify this MAPK
pathway.
Discussion
In the present study, we demonstrated that thymulin pre-
vented morphological, hemodynamic, and inflammatory
cardiopulmonary profile characteristics of MCT-induced
PH, whereas part of these effects were also observed in
MCT-treated animals injected with the thymulin’s vehicle
containing zinc. The pulmonary thymulin effect was likely
mediated through suppression of p38 pathway.
The pathogenesis of PH involves vasoconstriction, pul-
monary vascular remodeling, in situ thrombosis, and inflam-
mation. The inflammatory hypothesis of PH is supported
by both experimental and human studies (3–8). PH in-
duced by MCT is an experimental model with some simi-
larities with human PAH, such as hemodynamic repercus-
sions, histological changes, and high mortality (36). On the
other hand, it diverges from human PAH in the precocious
loss of endothelial barrier and in the inflammatory adven-
titial proliferation (15).
Inflammation is a main feature of the MCT model, as
demonstrated by early inflammatory cells recruitment (37)
and cytokine activation (9). To clarify the underlying mech-
anisms of MCT-induced PH, inflammatory cytokine expres-
sion and MAPK activation were examined. We observed an
FIG. 1. Lung and right ventricle IL-1, IL-6, and fractalkine mRNA levels, normalized for GAPDH (housekeeping gene) and expressed as AUs,
in the six studied groups: Ctrl plus S, Ctrl plus V, Ctrl plus T, MCT plus S, MCT plus V, and MCT plus T. P  0.05: , vs. Ctrl plus S; , vs.
Ctrl plus T; , vs. MCT plus S.
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increase in IL-6 gene expression not only in the lungs but also
in the right ventricle in the fourth week after MCT injection.
These findings confirm previous results from Bhargava et al.
(9) that demonstrated elevated levels of IL-6 at 48 h, 1 and 2
wk after MCT injection. We also evaluated IL-1 and frac-
talkine, other cytokines typically involved in human PH
pathophysiology, but in our study MCT did not increase
these cytokines in the lung tissue and had a very mild effect
in the myocardium.
MAPKs are important mediators of signal transduction
processes, and are activated in a variety of physiological and
pathological conditions. Lu et al. (38) found an increase in p38
MAPK activity in lungs from rats treated with MCT and
prevented the progression to PH through the administration
of a selective p38 inhibitor. On other hand, Morty et al. (39)
only observed a slight reduction in ERK1/2 phosphoryla-
tion, and no change in p38 MAPK phosphorylation. In our
study we demonstrated an increase in both p38 and JNK
phosphorylation in theMCT-treated animals, confirming the
involvement MAPK pathways in PH pathophysiology. On
the other hand, zinc exposure has activated several MAPKs
in airway epithelial cells (40, 41). Levels of MAPK phosphor-
ylation are regulated in opposite directions byMAPKkinases
and phosphatases (42), and zinc seems to act through inhi-
bition MAPK phosphatase activity (40). In fact, our data also
suggest that in Ctrl animals, zinc has an important role in
modulating MAPK, namely p38 phosphorylation. However,
in MCT-treated animals, zinc exposure did not change the
pattern of p38 activation, whereas thymulin treatment re-
sulted in a significant decrease in p38 phosphorylation.
FIG. 3. MAPK activities at pulmonary level in Ctrl plus S
animals (1), Ctrl plus V animals (2), Ctrl plus T animals (3),
MCT plus S animals (4), MCT plus V animals (5), andMCT
plus T animals (6). Western blot analysis of MAPK with
antibodies to p38, ERK1/2, and JNK1/2 (A), and to diphos-
phorylated forms of p38 (dp-p38), ERK1/2 (dp-ERK1/2), and
SAPK/JNK (dp-JNK1/2) (B). Ctrl loading was performed
using -tubulin (55 kDa). ERK1 and 2 correspond to 44 and
42 kDa, respectively. JNK1 and 2 correspond to 46 and 54
kDa, respectively. p38 corresponds to 38 kDa. Quantitative
analysis for dp-p38, dp-ERK1/2, and dp-JNK1/2 are pre-
sented as AUs in the six studied groups (C).
FIG. 2. Pulmonary IL-6 protein expression in different experimental groups by IHC. A, Ctrl plus S animals. B, Ctrl plus V animals. C, Ctrl
plus T animals. D, MCT plus S animals. E, MCT plus V animals. F, MCT plus T animals. All images are at the same magnification (200).
Arrows displayed IL-6 positive inflammatory cells.
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Thymulin has a potent immunomodulator effect, in ad-
dition to its action as a thymic hormone. Previous reports
have shown that thymulin prevents bleomycin-induced pul-
monary fibrosis (28), alloxan- and streptozotocin-induced
diabetes (43), myocarditis caused by the encephalomyocar-
ditis virus (44), and cisplatin- (29) and cephaloridine-induced
nephrotoxicity (30). In the setting of PH, our data revealed
that thymulin administration prevented biventricular hemo-
dynamic changes typically found in the MCT model. Part of
these effects had been also observed in animals treated with
vehicle containing zinc. These beneficial effects could be
partially explained by IL-6 suppression at pulmonary and
myocardium levels, reinforcing the pivotal role of IL-6 in PH
pathogenesis. In fact, delivery of recombinant IL-6 protein
reproduced themain hemodynamic and histological features
of PH in a rat model (17), and inhibition of IL-6 with dexa-
methasone (9) or serotonin antagonist (18) prevented the
development of PH. IL-6 exerts its effects by activation of the
janus kinase/signal transducers and activators of transcrip-
tion-signaling pathway and induction of the MAPK cascade
(45). In vitro, IL-6 stimulated lung branching through acti-
vation of p38-MAPK intracellular pathway (46). Recently,
Hagen et al. (47) demonstrated the presence of a negative
feedback loop between IL-6 and the bone morphogenetic
protein pathway mediated through p38 MAPK activity, and
proposed that IL-6 activation can be the inflammatory “sec-
ond hit” in patients with familial PAH with bone morpho-
genetic protein receptor 2 mutations.
In conclusion, we demonstrated that thymulin inhibited
the development of PH in the MCT model. This effect could
be related to the inhibition of proinflammatory IL-6 expres-
sion and suppression of p38 phosphorylation.
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